Catheter Precision Inc 2026年季度报告

FORM 10-Q ☒Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 OR ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No.001-38677 Catheter Precision, Inc. N/A(Former name, former address and former fiscal year, if changed since last report) Securities Registered under Section 12(b) of the Act: Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b‑2 of the Exchange Act). Yes☐No☒ As of the close of business on May 8, 2026, the registrant had 2,692,473shares of common stock, par value $0.0001 per share, outstanding. CATHETER PRECISION, INC.QUARTERLY REPORT ON FORM 10-Q TABLE OF CONTENTS PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS3Condensed Consolidated Balance Sheets (Unaudited)3Condensed Consolidated Statements of Operations (Unaudited)4Condensed Consolidated Statements of Stockholders’Equity (Unaudited)5Condensed Consolidated Statements of Cash Flows (Unaudited)6Notes to Condensed Consolidated Financial Statements (Unaudited)7ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS62ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK72ITEM 4. CONTROLS AND PROCEDURES72PART II. OTHER INFORMATIONITEM1.LEGAL PROCEEDINGS73ITEM1A.RISK FACTORS73ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS86ITEM 3. DEFAULTS UPON SENIOR SECURITIES86ITEM 4. MINE SAFETY DISCLOSURES86ITEM 5. OTHER INFORMATION86ITEM 6. EXHIBITS87SIGNATURES89 CATHETER PRECISION, INC.Condensed Consolidated Balance Sheets(in thousands, except per share data) CATHETER PRECISION, INC.Condensed Consolidated Statements of Operations(in thousands, except per share data)(Unaudited) CATHETER PRECISION, INC.Condensed Consolidated Statements of Stockholders' Equity(in thousands, except share data)(Unaudited) CATHETER PRECISION, INC.Condensed Consolidated Statements of Cash Flows(in thousands)(Unaudited) CATHETER PRECISION, INC.Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1. Organization and Nature of Operations The Company Catheter Precision, Inc. ("Catheter" or the "Company”) was incorporated in California on September 4, 2002, and reincorporated in Delaware in July2018.On January 9, 2023, Catheter entered into the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") with CatheterPrecision, Inc. (“Old Catheter”), a privately held Delaware corporation. Under the terms of the Merger Agreement, Old Catheter became a wholly ownedsubsidiary of Catheter, together referred to as the Company, in a stock-for-stock merger transaction (the "Merger"). The Company's operating activitiesprimarily related to Old Catheter's historical business, which comprisesthe design, manufacture and sale of new and innovative medical technologies in thefield of cardiac electrophysiology (“EP”). On February 6, 2026, the Company entered into an Acquisition Purchase Agreement with SEG Jets LLC ("SEG Jets"), whereby the Company agreed toacquire 19.98% of the issued and outstanding shares of common stock of Fly Flyte, Inc. ("FLYTE") held by SEG Jets. On March 9, 2026, the Companyentered into an Acquisition Purchase Agreement with Creatd, Inc. ("Creatd") and acquired the remaining 80.02% of the issued and outstanding shares ofcommon stock of FLYTE and all of FLYTE’s wholly owned consolidated subsidiaries, which included 100% equity ownership interest in Ponderosa Air,LLC. As a result of these transactions, the Company owns 100% of the issued and outstanding common stock of FLYTE common stock and its whollyowned consolidated subsidiaries. F